<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with trilineage <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (TMDS) in de novo <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) at diagnosis and remission were clinically evaluated between 1983 and 1996 </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with TMDS (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS) was observed in 20 (12%) of 162 patients with de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> at diagnosis </plain></SENT>
<SENT sid="2" pm="."><plain>Complete remission (CR) was achieved with combination chemotherapy in 12 (67%) of 18 AML/TMDS cases </plain></SENT>
<SENT sid="3" pm="."><plain>This CR rate was relatively worse than the rate of 78% (106/136 cases) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without TMDS, but this difference was not significant </plain></SENT>
<SENT sid="4" pm="."><plain>Disease-free survival curves also showed no difference between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without TMDS </plain></SENT>
<SENT sid="5" pm="."><plain>During remission, eight (67%) of 12 AML/TMDS cases had myelodysplastic remission marrow (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/MRM) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/MRM was also seen in seven (7%) of 106 AML cases without TMDS </plain></SENT>
<SENT sid="7" pm="."><plain>The actuarial disease-free survival was significantly lower in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/MRM than in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> without MRM (P = 0.0003) </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/MRM cases exhibited early leukaemic relapse; median remission duration was only 9 months </plain></SENT>
<SENT sid="9" pm="."><plain>Clonal changes occurred in two cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/TMDS and five cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>/MRM at the time of relapse </plain></SENT>
<SENT sid="10" pm="."><plain>These findings suggest that TMDS during remission predicts a poorer prognosis and early leukaemic relapse when compared with the absence of TMDS </plain></SENT>
</text></document>